Xia Zang

机构：Xiamen University, Jiangsu Provincial Center for Disease Control and Prevention

发表论文 11 篇 · 总被引 318 次 · h-index 8

代表论文

• Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials (2022 · The Lancet Respiratory Medicine · 被引 145)
• Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 73)
• Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial (2023 · 中国科学通报：英文版 · 被引 28)
• Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial (2023 · The Lancet Regional Health - Western Pacific · 被引 13)
• Substantial spillover burden of rat hepatitis E virus in humans (2025 · Nature Communications · 被引 12)
• Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China (2024 · Emerging Microbes & Infections · 被引 12)